AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI Healthcare screener that bring this theme to life and explains how they relate to today’s inflation, interest rate and geopolitical backdrop.
GeneDx Holdings (WGS)
Overview: GeneDx Holdings is a genomics company that focuses on whole exome and whole genome sequencing to diagnose rare and pediatric diseases, backed by an AI driven platform that supports hereditary risk and cancer testing. It also provides data and information services to healthcare providers and biopharma partners.
Operations: GeneDx generates about US$427.5 million of revenue mainly from its Gene Dx segment at US$423.1 million, with substantially all revenue currently coming from the United States.
Market Cap: US$1.94b
GeneDx sits at the heart of AI powered genomics, using its exome and genome tests, enriched rare disease database and Fabric Genomics technology to help doctors reach answers faster for complex pediatric cases while controlling costs. This is highlighted by studies showing healthcare cost reductions of up to 61%. Analysts are currently expecting revenue and earnings to increase, but the company is still loss making and relies on external funding, including a US$100 million term loan, which adds financing and execution risk if adoption slows or reimbursement tightens. For investors willing to weigh premium growth expectations, insider selling, governance quality and the latest coverage expansions, the key question is whether GeneDx’s AI and data advantages justify the market’s confidence.
AI powered genomics with cost cuts of up to 61% is a big story, but not the whole story. See how growth expectations, cash needs and funding risks line up in the 3 key rewards and 1 important warning sign
Medtronic (MDT)
Overview: Medtronic is a global medical device company that makes equipment used in heart care, brain and spine surgery, diabetes management, and hospital operating rooms, selling to hospitals and clinicians across the United States, Ireland, and the rest of the world.
Operations: Medtronic generates most of its revenue from Cardiovascular at about US$13.5b, Neuroscience at US$10.2b, Medical Surgical at US$8.6b, and Diabetes at US$3.0b, with additional smaller contributions from other units and adjustments.
Market Cap: US$111.2b
For investors looking at AI in healthcare but wanting an established dividend payer, Medtronic combines a broad device portfolio with use of AI in areas like surgical planning, cardiac care alerts and diabetes tools, backed by earnings growth, a 13% net margin and a 3.29% dividend yield. The company is also active in valve and neurovascular deals and new FDA clearances, yet still trades on a P/E below many peers, which may appeal if you want income and stability rather than rapid top line expansion. The trade off is slower revenue growth, modest ROE and reliance on external borrowing, so the key question is how that balance of quality, income and growth compares with pure play AI healthcare names.
Medtronic’s combination of earnings, a 13% net margin, a 3.29% dividend yield, and AI tools across surgery, cardiac care and diabetes is easy to like, but the real question is what the market might be missing in the analysis report for Medtronic
Stryker (SYK)
Overview: Stryker is a global medical technology company that supplies hospitals and clinicians with surgical equipment, AI assisted virtual care platforms, stroke and neurotechnology products, and joint replacement implants for hips, knees, shoulders and other extremities across about 61 countries.
Operations: Stryker generates about US$9.5b of revenue from Orthopaedics and US$15.6b from MedSurg and Neurotechnology, serving customers across the United States, Europe, the Middle East, Africa, Asia Pacific and other international markets.
Market Cap: US$126.9b
Stryker gives you direct exposure to AI in everyday hospital workflows through tools like its virtual care platforms and Mako smart robotics for joint replacement, backed by high quality earnings, forecast double digit earnings growth and a history of strong ROE. That strength comes with trade offs, including a premium P/E multiple, meaningful debt that needs watching and recent cyberattacks that disrupted ordering and manufacturing systems even as the company reports containment and restoration of most operations. For investors who like long term demand for orthopedic implants and surgical gear plus digital health add ons, the real question is whether that mix of quality, growth and cyber recovery risk is fully captured in today’s price.
Stryker’s premium P/E, strong ROE and AI driven hospital tools hint at a story the market may not have fully priced in yet, especially after recent cyber disruption, so the analyst forecasts for Stryker might surprise you
The three stocks in this article are only a starting point, and the full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaces 34 more companies with equally compelling AI healthcare narratives that you have not seen yet. Identify and analyze the specific catalysts that matter to you, from diagnostics and precision medicine to hospital efficiency and remote care, by using Simply Wall St to filter those narratives into your highest conviction ideas.
Take Control of Your Investment Journey
If Medtronic or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your top picks to a Watchlist to monitor the share price against the fair value for the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.
Curious About What Else You Could Be Exploring?
Fresh ideas can move quickly, with potential breakouts, fading momentum or stories flying under the radar for now. Do not get caught reacting late, get in early.
- Spot early movers in tiny, cash backed names by scanning the 32 elite penny stocks with strong financials before they jump onto everyone else's radar.
- Ride the build out of next generation computing by reviewing the curated 23 quantum computing stocks while sentiment and stories are still forming.
- Target income ideas with staying power by checking the hand picked 13 dividend fortresses before yields drop and prices move away from ideal entry points.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com